JG

Jeremy Goodwin

Chief Operating Officer

Bright Minds Biosciences

Bright Minds Biosciences Pipeline

DrugIndicationPhase
BMB-101Treatment-Resistant Depression (TRD)Phase 2
BMB-202Focal Onset Seizures / EpilepsyPhase 1/2